Nektar Therapeutics (NASDAQ: NKTR) stock exploded nearly 157% following news that Rezpeg, the company’s experimental ...

Dupixent has already picked up an additional approval as a treatment for severe asthma, and the French drugmaker is also eyeing testing it in phase 2 and 3 trials in chronic obstructive pulmonary ...

Lilly’s drug becomes an oral alternative to Sanofi and Regeneron’s biologic therapy Dupixent (dupilumab), which was recommended as a second-line option for moderate to severe atopic dermatitis ...

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color. GlobeNewswire Jun 7, 2025, 10:30:00 PM.